Опубликовано 02.03.2018 в 20:29
УДК: 616.15-008.1
В статье приводятся сведения о роли липопротеина (а) в патогенезе кардиоваскулярной патологии. Анализируется его участие в экспрессии рецепторов на клеточной поверхности, активации тромбоцитарной агрегации, миграции воспалительных клеток и индукции сосудистого ремоделирования.
"MYSTERIOUS" LIPOPROTEINE (A) AND ATHEROGENESIS: MOLECULAR-CELL INTERACTIONS
The article includes a review of experimental and clinical studies on the role of lipoprotein (a) in the pathogenesis of cardiovascular pathology. The author analyzes its involvement in the expression of receptors on the cell surface, the activation of platelet aggregation, the migration of inflammatory cells and the induction of vascular remodeling.
Библиографический список
Библиографический список
1. Арабидзе Г. Г., Теблоев К. И. Атеросклероз и факторы риска: клиническое значение аполипопротеинов в развитии ИБС: руководство для врачей. – М.: Литера, 2008. – 240 с.
2. Ройтберг Г. Е., Струтынский А. В. Внутренние болезни. Сердечно-сосудистая система: учеб. пособие. – 5-е изд. – М.: МЕДпресс-информ, 2017. – 896 с.
3. Deb A., Caplice N. M. Lipoprotein (a): new insights into mechanisms of atherogenesis and thrombosis // Clinical Cardiology. – 2004. – Vol. 27. – pp. 258–264.
4. Garelnabi M., Mahini H., Wilson T. Quercetin intake with exercise modulates lipoprotein metabolism and reduces atherosclerosis plaque formation // Journal of the International Society of Sports Nutrition. – 2014. – Vol. 11. – pp. 11–22.
5. Hong L., Daugherty A. Atherosclerosis: cell biology and lipoproteins // Current Opinion in Lipidology. – 2013. – Vol. 24, No. 1. – pp. 107–109.
6. Ioanna G. B., Heiner K. B. Lipoprotein (a): a current perspectives // Current Vascular Pharmacology. – 2011. – Vol. 9, No. 6. – pp. 682–692.
7. Koschinsky M. L, Marcovina S. M. Structure-function relationships in apolipoprotein (a): insights into lipoprotein (a) assembly and pathogenicity // Current Opinion in Lipidology. – 2004. – Vol. 15. – pp. 167–174.
8. McCormick S. P. Lipoprotein (a): biology and clinical importance // The Clinical Biochemist Review. – 2004. – Vol. 25, No. 1. – pp. 69–80.
9. Nakagami F., Nakagami M., Osako K. Estrogen attenuates vascular remodeling in Lp(a) transgenic mice // Atherosclerosis. – 2010. – Vol. 211, No. 1. – pp. 41–47.
10. Nordestgaard B. G., Chapman M. J., Ray K. Lipoprotein (a) as a cardiovascular risk factor: current status // European Heart Journal. – 2010. – Vol. 31, No. 23. – pp. 2844–2853.
11. Peyton K. J., Liu X., Yu Y. Activation of AMP-activated protein kinase inhibits the proliferation of human endothelial cells // Journal of Pharmacology and Experimental Therapeutics. – 2012. – Vol. 342, No. 3. – pp. 827–834.
12. Pellegrino M., Furmaniak-Kazmierczak E., Leblank J. C. The apolipoprotein (a) component of Lipoprotein (a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells // Journal of Biological Chemistry. – 2004. – Vol. 279, No. 8. – pp. 6526–6533.
13. Rowland C. M., Pullinger C. R., Luke M. M. Lipoprotein(a), LPA Ile4399Met, and fibrin clot properties // Thrombosis Research. – 2014. – Vol. 133, No. 5. – pp. 863–867.
14. Seimon T. A., Nadolsky M. J., Liao X. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress // Cell Metabolism. – 2010. – Vol. 12, No. 5. – pp. 467–482.
15. Siekmeir R., Scharnagl H., Kostner G. M. Variation of Lp(a) plasma concentrations in health and disease // The Open Clinical Chemistry Journal. – 2010. – Vol. 3. – pp. 72–89.
16. Sortirion S. N., Orlova V. V., Al-Fakhri N. Lipoprotein (a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin // FASEB Journal. – 2006. – Vol. 20, No. 3. – pp. 559–561.
17. Taleb A., Witztum J., Tsimikas S. Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events // Biomarkers in Medicine. – 2011. – Vol. 5, No. 5. – pp. 673–694.
18. Tasci T., Sukur Y. E., Ozmen B. Effect of transdermal and oral hormone replacement therapies on monocyte chemoattractant protein-1 levels: a randomized clinical trial // European Journal of Obstetrics & Gynecology. – 2014. – Vol. 176. – pp. 50–54.
19. Tayal D., Goswami B., Koner B., Mallika V. Role of homocysteine and lipoprotein (a) in atherosclerosis: an update // Biomedical Research. – 2011. – Vol. 22, No. 4. – pp. 391–405.
20. Tsimikas S., Witztum J. The role of oxidized phospholipids in mediating lipoprotein (a) atherogenicity // Current Opinion in Lipidology. – 2008. – Vol. 19, No. 4. – pp. 369–377.
Выходные данные статьи: Жучкова Т. Е. «Загадочный» липопротеин (а) и атерогенез: молекулярно-клеточные взаимодействия [Электронный ресурс] // Огарев-online. – 2018. – №4. – Режим доступа: https://journal.mrsu.ru/arts/zagadochnyj-lipoprotein-a-i-aterogenez-molekulyarno-kletochnye-vzaimodejstviya